Advanced Search

 

Study ID Status Title Patient Level Data
CNA10905 Completed An Open-Label, Single-Arm, Pharmacokinetic Study of Abacavir and its Intracellular Anabolite Carbovir Triphosphate Following Chronic Administration of an Abacavir 300mg BID Containing Regimen (Ziagen or Trizivir) in HIV Infected Patients
CNA109586 Completed Study of Once-Daily Abacavir/Lamivudine versus Tenofovir/Emtricitabine, Administered with Efavirenz in Antiretroviral-Naive, HIV-1 Infected Adult Subjects
CNA109586_1 Completed Study of Once-Daily Abacavir/Lamivudine versus Tenofovir/Emtricitabine, Administered with Efavirenz in Antiretroviral-Naive, HIV-1 Infected Adult Subjects at 96 weeks
CNA30017 Completed A Phase IIIb, Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of 2NRTI/Abacavir versus Continued 2NRTI/PI Treatment in HIV-1 Infected Subjects with Undetectable Plasma HIV-1 RNA Levels
CNA30018 Completed Open-Label Trial to Evaluate the Efficacy, Safety and Tolerance of 1592U89 (Abacavir) in Paediatric Infected Patients With Encephalopathy by HIV: Virological and Immunological Markers in CSF
CNA30021 Completed A Phase III, 48-week, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Abacavir (ABC) 600mg OAD vs ABC 300mg BID in Combination with Lamivudine (3TC) 300mg OAD and Efavirenz (EFV) 600mg OAD in Antiretroviral Therapy-Naïve HIV-1 Infected Subjects
CNA30024 Completed A Phase III, 1:1 Randomized, Double-Blind, Controlled, Multi-center Trial Comparing the Efficacy and Safety of Abacavir Versus Zidovudine When Combined With Lamivudine and Efavirenz for Treatment of HIV-1 Infection in Antiretroviral Therapy-Naïve Adults
CNA30027 & CNA30032 Completed A retrospective, case-control study to investigate genetic polymorphisms in HIV infected subjects who developed hypersensitivity following treatment with abacavir
CNA30027, CNA30032, CNA30021, CNA30024, EPV40001 Completed Final report from the analysis of candidate gene markers and genome-wide single nucleotide polymorphisms(SNPs) from two retrospective, case-control studies and three controlled clinical studies to investigate geneticpolymorphisms in HIV infected subjects who developed hypersensitivity following ...
CNAA1001 Completed A Phase I Trial to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of 1592U89 in HIV-Infected Children
CNAA3005 Completed A Phase III Randomised, Double-Blind, Multi-center Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Nave Subjects: 48 Week Report
CNAA3006 Completed A Double-Blind, Randomized, Multi-Center Trial to Evaluate the Safety and Efficacy of the Combination of 1592U89/Zidovudine (ZDV)/Lamivudine (3TC) Versus the Combination of Zidovudine (ZDV)/Lamivudine (3TC) in HIV-1 Therapy-Experienced Pediatric Patients
CNAA3007 Completed 1592U89 Open Label Protocol for Pediatric Patients with HIV-1 Infection
CNAA3008 Completed A 1592U89 Open Label Protocol for Adult Patients with HIV-1 Infection
CNAB1006 Completed A study to compare the pharmacokinetics of, and tolerability to, a single, oral, 600mg dose of 1592U89 in HIV positive subjects with and without liver disease.
CNAB2006 Completed A Phase II Open-Label Observational Study of Changes in Immune Function and Lymph Node Architecture During Long-Term Suppression of Viraemia Associated With Early Combination Therapy With Abacavir and Amprenavir in Antiretroviral-Naive HIV-1 Infected Subjects With a CD4+ Cell Count ?400 cells/mm3
CNAB3001 Completed A Phase III, Randomised, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 (Abacavir) in HIV-1 Infected Patients with AIDS Dementia Complex
CNAB3002 Completed A Randomised, Double-blind, Comparative, Parallel-group, Multicentre Trial to Evaluate the Safety and Efficacy of ABC Versus Placebo in Combination with Background Antiretroviral Therapy in HIV-1 Infected Antiretroviral Therapy Experienced Subjects with CD4+ cell counts ? 100 cells/mm³ and Plasm ...
CNAB3003 Completed A Randomized, Double-Blind, Parallel-Group, Multicenter Trial to Evaluate the Safety and Efficacy of 1592U89 in Combination with Lamivudine (3TC) and Zidovudine (ZDV) versus 3TC/ZDV in HIV-1 Infected Antiretroviral Therapy Naive Subjects with CD4+ cell counts ?100 cells/mm³
CNAB3004 Completed An Open-Label Phase III Study to Allow Continued Access to Abacavir for HIV-Infected Adults who Have Completed a Clinical Study From the GlaxoSmithKline International Development Programme for Abacavir (CNAB3004)
CNAB3014 Completed A Phase IIIb Randomised, Open-Label, Multi-centre Study to Evaluate the Safety and Efficacy of ABC/3TC/ZDV Versus IDV/3TC/ZDV in HIV-1 Infected Antiretroviral Therapy Naïve Subjects: 48 Week Report
CNAF3016 Completed A Pilot Study to assess the Efficacy and Safety of a quadritherapy with Combivir, Abacavir, Nelfinavir switching from week 16 to (TZV), Nelfinavir for Antiretroviral Therapy in HIV-infected Naive Subjects with a viral load > 50 000 copies/mL
CNAF3021 Completed Long term follow-up of 2 triple combinations CombivirTM + Ziagen™ and Combivir™ + Viracept™ started in HIV-1 infected antiretroviral therapy naïve subjects within 2 years in study CNAF3007-Ecureuil.
COD10001 Completed A pilot open-labeled, randomized, parallel cohort, pharmacokinetic and pharmacodynamic, multicenter trial of zidovudine (RETROVIR) 600 mg once daily compared to zidovudine 300 mg BID monotherapy for 14 days in HIV infected, therapy naïve patients.
COD20002 Completed A Phase II, Open-Label, Multicenter, Randomized, Parallel Group, 14 Day Pilot Study of Monotherapy with Zidovudine 600mg Once Daily Compared to Zidovudine 300mg Twice Daily in HIV-Infected, Antiretroviral-Naïve Subjects.

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.